证券之星消息，8月13日医疗服务板块较上一交易日上涨4.02%，创新医疗领涨。当日上证指数报收于 3683.46，上涨0.48%。深证成指报收于11551.36，上涨1.76%。医疗服务板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流入19.62亿元，游资资金净流出7449.63万元，散户资 金净流出18.88亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603259 | 药明康德 | = 11.30 乙 | 11.46% | -1.00 Z | -1.02% | -10.30 Z | -10.45% | | 300759 康龙化成 | | 2.48亿 | 9.09% | 4825.42万 | 1.77% | -2.96 Z | - ...

Investment Rating - The report maintains a strong investment rating for the pharmaceutical and biotechnology sector, indicating it is expected to outperform the market [7]. Core Insights - The report highlights the recent policy push for brain-computer interface (BCI) technology, emphasizing the potential for a trillion-dollar market opportunity. The government aims to cultivate 2-3 global leading companies in this field by 2030, showcasing the urgency to position within this emerging industry [4][16][17]. Market Review - The CITIC Pharmaceutical Index fell by 0.8% during the week of August 4-8, 2025, underperforming the CSI 300 Index by 2.0 percentage points. However, since the beginning of 2025, the CITIC Pharmaceutical and Biotechnology Index has risen by 21.8%, outperforming the CSI 300 Index by 17.5 percentage points [3][31]. - The top five performing stocks during this week included Nanmo Biology (+42.5%), Haichen Pharmaceutical (+41.3%), Sainuo Medical (+39.5%), Chengyi Pharmaceutical (+35.8%), and Dabo Medical (+31.5%) [3][48]. Investment Focus - The report suggests focusing on innovative drugs, particularly those with revenue and commercialization capabilities, as well as medical devices, which are expected to see a policy turning point. The report encourages identifying high-performing stocks as companies begin to disclose mid-year results [5][16]. - Specific companies to watch include Mailland, Xiangyu Medical, Chengyitong, Innovation Medical, and Sanbo Brain Science, which are positioned well within the BCI sector [4][16][17]. Policy Developments - Recent policies from seven ministries, including the Ministry of Industry and Information Technology, outline a clear development roadmap for BCI technology, covering aspects from technical breakthroughs to global competitiveness [4][18][22]. - By 2027, key technological breakthroughs are expected, with the establishment of an advanced technical and industrial system. The BCI market is projected to grow significantly, with the global medical BCI market expected to reach $40 billion by 2030 and $145 billion by 2040 [22][23]. Company Developments - Notable companies in the BCI space include: - **Qiangnao Technology**: Focused on non-invasive BCI, received FDA approval for its smart bionic hand. - **Nerve Tiger Technology**: Achieved real-time motion decoding and language understanding with its invasive BCI technology. - **Mikron Medical**: Developing a range of non-invasive BCI products and collaborating with hospitals for research [29][30]. This summary encapsulates the key points from the industry report, focusing on investment opportunities, market performance, and policy developments within the pharmaceutical and biotechnology sectors, particularly in relation to brain-computer interfaces.

8月8日，百诚医药大宗交易成交28.62万股，成交额1653.09万元，占当日总成交额的8.68%，成交均价 57.76元，较市场收盘价57.81元折价0.09%，其中最高成交价57.81元，最低成交价57.61元。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-08-08 | 301096 | 百诚医药 | 57.81 | 21.43 | | 1,238.87 东北证券股份有限 | 东北证券股份有限 | | | | | | | | 公司杭州教工路证 | 公司杭州教工路证 | | | | | | | | 券营业部 | 券营业部 | | 2025-08-08 | 301096 | 百诚医药 | 57.61 | 7.19 | 414.22 | 东北证券股份有限 | 华宝证券股份有限 | | | | | | | | 公司杭州教工路证 | 公司杭州学院路证 | | ...

Group 1 - The core point of the announcement is the decision by Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. to use part of the raised funds to permanently supplement its working capital, amounting to RMB 363.87 million [1][2]. - The decision was made during the third meeting of the fourth supervisory board held on August 4, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2]. - The use of the funds is aimed at reducing financial costs, enhancing operational efficiency, and improving profitability, while ensuring that it does not affect the construction of investment projects or the company's daily operations [1][2]. Group 2 - The proposal to use the raised funds requires approval from the company's shareholders' meeting, with a voting result of 3 votes in favor, 0 against, and 0 abstentions [2]. - The decision aligns with the regulations set forth in the "Regulations on the Supervision of Raised Funds by Listed Companies" and other relevant guidelines, ensuring no harm to the interests of the company or minority shareholders [1].

证券代码：301096 证券简称：百诚医药 公告编号：2025-033 （一）审议通过《关于部分超募资金永久补充流动资金的议案》 为提高募集资金的使用效率、满足公司流动资金需求，根据《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《上市公 司募集资金监管规则》等规定，公司拟使用首次公开发行股票的超募资金 保荐机构就本议案发表了核查意见。 杭州百诚医药科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 杭州百诚医药科技股份有限公司（以下简称"公司"）第四届董事会第三次会 议于 2025 年 8 月 4 日（星期一）在公司会议室以现场结合通讯的方式召开。会 议通知已于 2025 年 7 月 30 日通过邮件的方式送达各位董事。本次会议应出席董 事 9 人，实际出席董事 9 人（其中 3 位董事以通讯方式出席会议）。 会议由董事长楼金芳主持，监事、高级管理人员列席。会议召开符合有关法 律、法规、规章和《公司章程》的规定。经各位董事认真审议，会议形成了如下 决议： 二、董事会会议审议情况 具体内容详见 ...

（文章来源：证券日报） 证券日报网讯 8月4日晚间，百诚医药发布公告称，公司第四届董事会第三次会议审议通过了《关于部 分超募资金永久补充流动资金的议案》《关于提请召开2025年第二次临时股东大会的议案》。 ...

（文章来源：证券日报） 证券日报网讯 8月4日晚间，百诚医药发布公告称，公司第四届监事会第三次会议审议通过了《关于部 分超募资金永久补充流动资金的议案》。 ...

证券日报网讯8月4日晚间，百诚医药（301096）发布公告称，公司将于2025年8月20日召开2025年第二 次临时股东大会。本次股东大会将审议《关于部分超募资金永久补充流动资金的议案》。 ...

Group 1 - The core point of the article is that Baicheng Pharmaceutical announced a board meeting to discuss the use of excess raised funds for permanent working capital supplementation [1] - For the fiscal year 2024, Baicheng Pharmaceutical's revenue composition is as follows: 90.22% from CRO business, 5.2% from CDMO business, and 4.58% from commercial production [1] - As of the report date, Baicheng Pharmaceutical has a market capitalization of 6.5 billion yuan [1] Group 2 - A warning from a German executive in China highlights the dangers of free autonomous driving services, stating it could lead to a disaster for the entire industry [1]

关于杭州百诚医药科技股份有限公司 部分超募资金永久补充流动资金的核查意见 国金证券股份有限公司（以下简称"保荐机构"）为杭州百诚医药科技股份 有限公司（以下简称"百诚医药"或"公司"）首次公开发行股票并在创业板上 市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业 板股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》《上市公司募集资金监管规则》等规则的要求，对百诚医药部分超 募资金永久补充流动资金事项进行了审慎核查，核查情况及核查意见如下： 一、募集资金的情况 经中国证券监督管理委员会《关于同意杭州百诚医药科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2021]3566 号）核准，公司首次公开发行 人民币普通股（A 股）股票 27,041,667 股,每股面值 1 元，每股发行价格为人民 币 79.60 元，募集资金总额为人民币 2,152,516,693.20 元，扣除本次发行费用人 民币 289,086,604.79 元后，实际募集资金净额为人民币 1,863,4 ...